Top-Rated StocksTop-RatedNASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis $11.43 -0.13 (-1.12%) (As of 05:26 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Rocket Pharmaceuticals Stock (NASDAQ:RCKT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rocket Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.21▼$11.6150-Day Range$11.35▼$18.8252-Week Range$11.15▼$32.53Volume1.19 million shsAverage Volume844,689 shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$48.80Consensus RatingModerate Buy Company OverviewRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More… Rocket Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks97th Percentile Overall ScoreRCKT MarketRank™: Rocket Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 46th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rocket Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.85) to ($2.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -4.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.40% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.81 Percentage of Shares Shorted11.40% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 6.31%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.78 News SentimentRocket Pharmaceuticals has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Rocket Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest11 people have searched for RCKT on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat Follows20 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $176,045.00 in company stock.Percentage Held by Insiders28.50% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RCKT Stock News Headlines3 Small-Cap Stocks That Are Ready to Rocket Higher (RCKT)With lower interest rates and lower corporate taxes more likely, it's a good time to consider three small-cap stocks that present a buying opportunityNovember 27, 2024 | marketbeat.comMartin Wilson Sells 1,175 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) StockNovember 26, 2024 | insidertrades.comCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.December 23, 2024 | ProsperityPub (Ad)Federal watchdog sues Rocket Companies' subsidiary for alleged kickbacksDecember 23 at 5:45 PM | msn.comEvercore ISI Reaffirms Their Buy Rating on Rocket Pharmaceuticals (RCKT)December 23 at 12:44 PM | markets.businessinsider.comRocket Pharmaceuticals' SWOT analysis: gene therapy stock poised for growthDecember 23 at 12:40 AM | uk.investing.comHead to Head Review: InMed Pharmaceuticals (NASDAQ:INM) vs. Rocket Pharmaceuticals (NASDAQ:RCKT)December 19, 2024 | americanbankingnews.comJefferies Initiates Coverage of Rocket Pharmaceuticals (RCKT) with Buy RecommendationDecember 18, 2024 | msn.comSee More Headlines RCKT Stock Analysis - Frequently Asked Questions How have RCKT shares performed this year? Rocket Pharmaceuticals' stock was trading at $29.97 at the beginning of the year. Since then, RCKT shares have decreased by 61.9% and is now trading at $11.43. View the best growth stocks for 2024 here. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its quarterly earnings data on Monday, August, 5th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.02. Who are Rocket Pharmaceuticals' major shareholders? Top institutional investors of Rocket Pharmaceuticals include Wellington Management Group LLP (12.33%), Westfield Capital Management Co. LP (4.94%), Maverick Capital Ltd. (4.52%) and State Street Corp (3.40%). Insiders that own company stock include Rtw Investments, Lp, Gaurav Shah, Gotham Makker, Kinnari Patel, Jonathan David Schwartz, Mark Andrew White, Martin Wilson and John Militello. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Marinus Pharmaceuticals (MRNS), Waste Connections (WCN), Humana (HUM), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/05/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees240Year Founded2018Price Target and Rating Average Stock Price Target$48.80 High Stock Price Target$65.00 Low Stock Price Target$29.00 Potential Upside/Downside+333.0%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($2.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.62% Return on Assets-54.17% Debt Debt-to-Equity Ratio0.06 Current Ratio6.05 Quick Ratio6.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book2.06Miscellaneous Outstanding Shares91,157,000Free Float65,177,000Market Cap$1.03 billion OptionableOptionable Beta1.01 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RCKT) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.